Inhibitors of HER2/neu (erbB-2) signal transduction
- Author
- ARTEAGA, Carlos L; CHINRATANALAB, Wichai; CARTER, Mary Beth
Department of Veterans Affairs Medical Center, Nashville, TN, United States
Departments of Medicine and Cell Biology, Vanderbilt University School of Medicine, Nashville, TN, United States
Vanderbilt-Ingram Cancer Center, Nashville, TN, United States - Conference title
- Targeting HER2: Recent developments and future directions for breast cancer patients
- Conference name
- Targeting HER2: Recent Developments and Future Directions for Breast Cancer Patients. Satellite Symposium (Paris 2000-02-02)
- Author (monograph)
- HORTOBAGYI, Gabriel N (Editor)1
[1] Department of Breast Medical Oncology, University of Texas, M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, United States - Source
Seminars in oncology. 2001, Vol 28, Num 6, pp 30-35 ; SUP18 ; ref : 32 ref
- CODEN
- SOLGAV
- ISSN
- 0093-7754
- Scientific domain
- Medical oncology
- Publisher
- Elsevier, Philadelphia, PA
- Publication country
- United States
- Document type
- Conference Paper
- Language
- English
- Keyword (fr)
- Anticorps monoclonal Cible Glande mammaire Homme Inhibiteur Produit gène Protéine transmembranaire Récepteur facteur croissance Transduction signal Tumeur maligne Vaccin Vaccination Gène erbB2 Gène erbB Oncoprotéine Protéine HER2 Glande mammaire pathologie
- Keyword (en)
- Monoclonal antibody Target Mammary gland Human Inhibitor Gene product Transmembrane protein Growth factor receptor Signal transduction Malignant tumor Vaccine Vaccination Oncoprotein Mammary gland diseases
- Keyword (es)
- Anticuerpo monoclonal Blanco Glándula mamaria Hombre Inhibidor Producto gene Proteína transmembranar Receptor factor crecimiento Transducción señal Tumor maligno Vacuna Vacunación Glándula mamaria patología
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents / 002B02R03 Immunotherapy
- Discipline
- Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 13483597
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1016/S0093-7754(01)90106-X 
https://dx.doi.org/10.1016/S0093-7754(01)90106-X
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0093-7754(01)90106-X\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:51:\"Inhibitors of HER2\/neu (erbB-2) signal transduction\";s:9:\"\u0000*\u0000jtitle\";s:20:\"Seminars in oncology\";s:9:\"\u0000*\u0000stitle\";s:12:\"Semin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:2:\"28\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:2:\"30\";s:8:\"\u0000*\u0000epage\";s:2:\"35\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0093-7754\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"ARTEAGA\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Carlos L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:21:\"CHINRATANALAB, Wichai\";i:1;s:17:\"CARTER, Mary Beth\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"SOLGAV\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:5:\"SUP18\";s:9:\"\u0000*\u0000btitle\";s:84:\"Targeting HER2: Recent developments and future directions for breast cancer patients\";s:8:\"\u0000*\u0000title\";s:51:\"Inhibitors of HER2\/neu (erbB-2) signal transduction\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0093-7754(01)90106-X\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:51:\"Inhibitors of HER2\/neu (erbB-2) signal transduction\";s:9:\"\u0000*\u0000jtitle\";s:20:\"Seminars in oncology\";s:9:\"\u0000*\u0000stitle\";s:12:\"Semin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:2:\"28\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:2:\"30\";s:8:\"\u0000*\u0000epage\";s:2:\"35\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0093-7754\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"ARTEAGA\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Carlos L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:21:\"CHINRATANALAB, Wichai\";i:1;s:17:\"CARTER, Mary Beth\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"SOLGAV\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:5:\"SUP18\";s:9:\"\u0000*\u0000btitle\";s:84:\"Targeting HER2: Recent developments and future directions for breast cancer patients\";s:8:\"\u0000*\u0000title\";s:51:\"Inhibitors of HER2\/neu (erbB-2) signal transduction\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0093-7754(01)90106-X\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0093-7754(01)90106-X\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:51:\"Inhibitors of HER2\/neu (erbB-2) signal transduction\";s:9:\"\u0000*\u0000jtitle\";s:20:\"Seminars in oncology\";s:9:\"\u0000*\u0000stitle\";s:12:\"Semin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:2:\"28\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:2:\"30\";s:8:\"\u0000*\u0000epage\";s:2:\"35\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0093-7754\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"ARTEAGA\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Carlos L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:21:\"CHINRATANALAB, Wichai\";i:1;s:17:\"CARTER, Mary Beth\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"SOLGAV\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:5:\"SUP18\";s:9:\"\u0000*\u0000btitle\";s:84:\"Targeting HER2: Recent developments and future directions for breast cancer patients\";s:8:\"\u0000*\u0000title\";s:51:\"Inhibitors of HER2\/neu (erbB-2) signal transduction\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0093-7754(01)90106-X\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:51:\"Inhibitors of HER2\/neu (erbB-2) signal transduction\";s:9:\"\u0000*\u0000jtitle\";s:20:\"Seminars in oncology\";s:9:\"\u0000*\u0000stitle\";s:12:\"Semin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:2:\"28\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:2:\"30\";s:8:\"\u0000*\u0000epage\";s:2:\"35\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0093-7754\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"ARTEAGA\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Carlos L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:21:\"CHINRATANALAB, Wichai\";i:1;s:17:\"CARTER, Mary Beth\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"SOLGAV\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:5:\"SUP18\";s:9:\"\u0000*\u0000btitle\";s:84:\"Targeting HER2: Recent developments and future directions for breast cancer patients\";s:8:\"\u0000*\u0000title\";s:51:\"Inhibitors of HER2\/neu (erbB-2) signal transduction\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0093-7754(01)90106-X\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:51:\"Inhibitors of HER2\/neu (erbB-2) signal transduction\";s:9:\"\u0000*\u0000jtitle\";s:20:\"Seminars in oncology\";s:9:\"\u0000*\u0000stitle\";s:12:\"Semin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:2:\"28\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:2:\"30\";s:8:\"\u0000*\u0000epage\";s:2:\"35\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0093-7754\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"ARTEAGA\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Carlos L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:21:\"CHINRATANALAB, Wichai\";i:1;s:17:\"CARTER, Mary Beth\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"SOLGAV\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:5:\"SUP18\";s:9:\"\u0000*\u0000btitle\";s:84:\"Targeting HER2: Recent developments and future directions for breast cancer patients\";s:8:\"\u0000*\u0000title\";s:51:\"Inhibitors of HER2\/neu (erbB-2) signal transduction\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
